诺诚健华(688428):诺诚健华医药有限公司2027年度“提质增效重回报”2.0行动方案(英文版)
InnoCarePharmaLimited 2027“QualityImprovement,EfficiencyEnhancement andHighReturn”2.0ActionPlan InnoCarePharmaLimited(the“Company”),inordertoimplementtherelevantrequirementsoftheStateCouncil’sOpinionsonFurtherImprovingQualityofListedCompanies, actively responds to the Shanghai Stock Exchange’s Proposal onLaunchingthe“QualityImprovement,EfficiencyEnhancementandHighReturn”2.0SpecialActionforSSE-ListedCompaniesandtheaccompanyingmodeltexts,practicesthe “investor-oriented” development philosophy, effectively fulfills the primaryresponsibilities of a listed company, and promotes the Company’s high-qualitydevelopment.Onthebasisoftheoriginalactionplan,theCompanyhasformulatedthe2027“QualityImprovement,EfficiencyEnhancementandHighReturn”2.0ActionPlan,whichisherebyreportedasfollows: I. OverviewoftheCompany’sOperations TheCompanyisaninnovativebiopharmaceuticalenterprisedrivenbyoutstandingin-houseR&Dcapabilities,focusingonareaswithsignificantunmetclinicalneeds,suchasoncologyandautoimmunediseases,anddevelopingbest-in-classorfirst-in-classdrugswithbreakthroughpotential.TheCompany’sexistingpipelinedrugscovermultipleinnovativetargetsandindicationswithstrongmarketprospects,includingsmall molecules, monoclonal antibodies, bispecific antibodies andADCs for thetreatmentofhemato-oncology,variousautoimmunediseasesandsolidtumors.LedbyamanagementteamwithextensiveexperienceinR&D,manufacturingandcommercialization,theCompanyhasbuiltanintegratedbiopharmaceuticalplatformthatbalancesR&Dqualityandspeed,andhasestablishedaproductpipelinecoveringmultiplehighlypromisingpopulartargets,committedtodevelopingandprovidingpatientswithmultipleinnovativedrugsandtherapies. (I)AnalysisofOperatingPerformancebySegment 1. HematologicOncology HematologiconcologyistheCompany’scurrentcoregrowthengine,supportedbycommercializedproducts,continuouslyexpandingindicationsandadifferentiatedpipelineofnext-generationtherapies. Orelabrutinib has demonstrated strong commercial momentum in 2026.Theapprovalandreimbursementcoverageofthe1LCLL/SLLindicationfurtherexpandedpatientaccessibilityandstrengtheneditsmarketposition.Inaddition,orelabrutinibremainstheonlyBTKinhibitorapprovedinChinaforr/rMZL,furtherreinforcingitsdifferentiatedprofile.Orelabrutinibhasfurtherextendeditsglobalregistrationfootprint,withapprovalgrantedforther/rMCLindicationinAustraliaandther/rMZLindicationinSingapore,furthervalidatingitsdifferentiatedclinicalprofileandreinforcingitspotentialasagloballycompetitiveBTKinhibitor. TafasitamabwasapprovedbytheNMPAin2025foradultpatientswithr/rDLBCLwho are not eligible for ASCT. The product further enriched the Company’shematologiconcologyportfolioandclarifieditsclinicalpositioningthroughupdatedrecommendationsintheChineseSocietyofClinicalOncology(CSCO)GuidelinesfortheDiagnosisandTreatmentofMalignantLymphoma.TafasitamabincombinationwithlenalidomidewasupgradedtoaClassIrecommendedregimenforsecond-lineandlatertreatmentofDLBCL,whiletafasitamabincombinationwithrituximabandlenalidomide was newly included as a Class I recommended regimen forrelapsed/refractoryfollicularlymphoma(r/rFL). Mesutoclax(ICP-248)hascontinuedtoadvanceasastrategicgrowthpillarofthehematologyfranchise.MultipleregistrationaltrialsareprogressingacrossCLL/SLL,MCL,MZLandAML.Updatedclinicaldatapresentedatthe2026ASCOAnnualMeetingfurthersupportedthepotentialofmesutoclax(ICP-248)acrossmultiplenon-Hodgkin lymphomas and myeloid malignancies. With an expanding commercialfoundation and multiple late-stage clinical programs advancing, the Company ispositionedtofurtherstrengthenitsleadershipinhematologiconcology.2. AutoimmuneDiseases In autoimmune diseases, the Company has established a differentiated andincreasinglymatureportfoliotargetingbothB-cellandT-cell-mediatedpathways,anchoredbyoralsmall-moleculeinnovation. (1)Orelabrutinibhasmaderapidclinicalprogressacrossmultipleautoimmuneindications: ①ITP:TheNewDrugApplication(NDA)submissionwasacceptedbythe NMPAinMay2026followingthecompletionoftheregistrationalPhaseIIIstudy.②SLE:PositivePhaseIIbdatapresentedatEULAR2026supportedcontinuedPhaseIIIclinicaldevelopment,andpatientenrollmentinthePhaseIIIstudyiscurrentlyongoing. ③MS:GlobalPhaseIIIprogramsinPPMSandnaSPMSareongoingthrough thecollaborationwithZenasBioPharma,Inc.,withongoingpatientenrollment.(2)Soficitinib(ICP-332)hascontinuedtoadvanceasakeyT-cellpathwayasset:①The Phase III registrational trial in moderate-to-severe atopic dermatitiscompleted patient enrollment, achieved its primary endpoint and multiple keysecondaryendpoints. ②ThePhaseIIportionofthePhaseII/IIIprograminnon-segmentalvitiligoachieveditsprespecifiedprimaryendpoint,withPhaseIIIstudydesigndiscussionsongoingwiththeCDE. ③Additional indications, including CSU, psoriasis and PN, continued toprogresssteadily. (3)Fadeucravacitinib(ICP-488),aselectiveallostericTYK2inhibitor,hasfurtherstrengthenedtheCompany’sautoimmunepipeline: ①ThePhaseIIIpsoriasisstudycompletedpatientenrollmentandachieveditsprimaryendpoint. ②ThePhaseIIstudiesincutaneouslupuserythematosus(CLE)andSj?gren’ssyndromeprogressedsmoothly,withclinicaldevelopmentadvancingcomprehensivelyacrossmultipleautoimmuneindications. Beyondlate-stageprograms,theCompanycontinuedtoexpanditsautoimmunepipeline.ICP-538,aVAV1-targetedcompound,enteredclinicaldevelopmentwithPhaseISAD/MADcohortsongoing.ICP-054,anoralIL-17smallmolecule,initiatedPhaseIclinicaldevelopment,withSAD/MADescalationunderway.ICP-B161(aTL1A/IL-23p19bispecificantibody)wasapprovedforclinicaltrialinOctober2026forthetreatmentofinflammatoryboweldisease(IBD)andotherautoimmunediseases.3. SolidTumors Insolidtumors,theCompanyisbuildingacompetitiveportfoliocombiningtargetedtherapiesandproprietaryADCtechnologies. Zurletrectinib(ICP-723)receivedNMPAapprovalforNTRKfusion-positivesolidtumors,markingtheapprovalandlaunchoftheCompany’sfirstsolidtumortherapy;theNDAforthepediatricindicationhasalsobeensubmitted. ThreecandidatesfromtheCompany’sproprietaryADCplatformhaveenteredtheclinicalstage.ICP-B794,aB7-H3-targetedADC,isdemonstratingencouragingearlysafetyandpharmacokineticsignals.ICP-B208,aCDH17-targetedADC,isinPhaseIclinicaldoseescalation.ICP-B381,adifferentiatedPSMA/STEAP1dual-targetingADC,hascompletedfirst-patientenrollmentinitsPhaseIclinicaltrialforthetreatmentofprostatecancerandothersolidtumors. (II)KeyFinancialIndicatorsforthePastThreeYears Unit:RMBtenthousand Currency:RMB
1. OperatingRevenue: During2023–2024,thegrowthintheCompany’soperatingrevenuewasprimarilydrivenbythecoreproductorelabrutinib.FollowingtherenewalofNRDLandapproval of new indications, orelabrutinib achieved continuous hospitalpenetrationandincreasedprescriptionvolume,representingasteadyramp-upphase in the commercialization of such drug. Since 2025, the inclusion oforelabrutinibforfirst-lineCLL/SLLindicationintotheNRDLhasdrivensalesvolume,whiletheapprovalandlaunchoftafasitamabandzurletrectinibformedamulti-productcommercialportfolio.Coupledwiththerecognitionofsignificantmilestone income from global out-licensing, operating revenue for the yearincreasedby135.3%year-on-year.Inthefirstthreequartersof2026,orelabrutinib,tafasitamabandzurletrectinibcontinuedtocontributepharmaceuticalrevenue,whilesubsequentmilestonesfrompreviousoverseascollaborationscontinuedtoberealized,resultinginan88.2%year-on-yearincreaseinoperatingrevenue.Overall,theCompany’srevenuegrowthstemmedfromthecombinedeffectsofclinical translation of in-house innovation pipelines, construction ofcommercialization systems, and global asset out-licensing, with continuousimprovementinoperationalquality. 2. NetProfit/(Loss)AttributabletoOwnersoftheParentandAfterDeductingNon-recurringGainsandLosses During2023–2024,theCompanywasinthephaseofcommercializationramp-upfor innovative drugs and continuous pipeline investment, with net profitattributabletoownersoftheparentandafterdeductingnon-recurringgainsandlossesbeingnegative.However,withthesalesvolumegrowthofcoreproductsandrefinedcostcontrol,thelossmarginnarrowedyearbyyear.In2025,relyingonthesalesvolumegrowthofcoredrugsandtherecognitionofglobalout-licensingmilestoneincome,theCompanyachievedprofitabilityforthefirsttimeinbothnetprofitattributabletoownersoftheparentandafterdeductingnon-recurringgainsandlosses.Inthefirstthreequartersof2026,withthefurtherenrichmentoftheproductmatrixandcontinuousrealizationofincomefromout-licensingbusiness,profitabilitycontinued.ThemaindriversoftheCompany’sprofitchangesarethematuringcommercializationofinnovativedrugs,valuerealization from global business development, and improved quality andefficiency of costs. The profit is mainly from principal businesses, namelypharmaceuticalsalesrevenueandbusinessdevelopmentincome,withthechangetrendofnetprofitattributabletoownersoftheparentafterdeductingnon-recurringgainsandlossesbeinggenerallyconsistentwiththatofnetprofitattributabletoownersoftheparent. 3. TotalAssetsandNetAssets During2023–2024,theCompanywasinthepre-profitabilitystagefeaturingcommercializationramp-upandcontinuouspipelineinvestment.Operatinglossesledtoadecreaseinretainedearnings,leadingtoaslightdeclineintotalassetsandnetassetsattributabletoownersoftheparentin2024.In2025,benefitingfromthesalesvolumegrowthofcoredrugsandrealizationofglobalout-licensingmilestoneincome,theCompanyachievedannualprofitabilityforthefirsttime,withoperatingcashflowturningpositive.Endogenousprofitaccumulationdrovetheincreaseinnetassets,resultingingrowthintotalassetsandnetassets.Inthefirst three quarters of 2026, with continuous realization of profits, retainedearningscontinuedtoincrease,andtheassetscalemaintainedsteadygrowth.TheCompany’sassetstructureismainlycomposedofcashandcashequivalents,financialassets,andoperatingreceivables,witharelativelylowproportionoflong-termassets.Endogenouscapitalaccumulationdrivenbyprofitabilityisthecorepathforthecurrentgrowthinnetassets.TheCompanyadherestoalow-leverageoperatingstrategy,prioritizingthesupportofbusinessexpansionthroughoperatingprofitsandoperatingcashflow,resultinginacontinuouslyrobustfinancialstructure. 4. GrossProfitMargin During2023–2024,thesalesvolumegrowthofthecoreproductorelabrutinibunlockedproductionscaleeffects,liftingtheprofitabilityofsingledrugproducts.In2025,thegrossprofitmarginincreasedsignificantly,primarilyduetotheinclusionofhigh-marginglobalpipelineout-licensingmilestoneincomeintooperatingrevenue.Theoptimizationofrevenuestructure,coupledwithcontinuousimprovementofpharmaceuticalproductioncosts,significantlyimprovedearningsquality. In the first three quarters of 2026, with the further expansion ofpharmaceuticalsalesscaleandfurtherdiversificationofrevenuestructure,theconsolidatedgrossprofitmarginremainedrelativelystable,layingasolidearningsfoundation. 5. R&DInvestment,R&DInvestmentasaPercentageofOperatingRevenue,andYear-on-YearGrowthRateofR&DInvestment From 2023 to the first three quarters of 2026, the Company’s total R&Dinvestmentcontinuedtoincrease,witharelativelystableyear-on-yeargrowthrateinR&Dinvestment.ThecoverageofR&Dinvestmentbyrevenuecontinuedtostrengthen,withR&Dinvestmentasapercentageofoperatingrevenuedecreasingfrom102.53%in2023to37.40%inthefirstthreequartersof2026.Intermsofqualityandefficiencyimprovement,theCompanycontinuouslyoptimizestheallocation and precision of R&D resources, pushes forward innovation oftechnologyplatformsandinvestmentsinclinicaltrialsaimedatacceleratingtransformation. Meanwhile, commercialization and business developmentbusinesseshavebroughtrapidrevenuegrowth,withtheoutputefficiencyofR&Dinvestment continuously improving, achieving a dynamic balance betweeninnovationinvestmentandoperationalbenefits. II.Management’sDiscussionandAnalysisontheCompany’sCurrentStatusofQualityImprovement,EfficiencyEnhancementandHighReturn (I)AnalysisofOperatingIndicators 1. SelectionofOperatingIndicators
(1)GrowthRateofR&DInvestment TheinnovativedrugindustryischaracterizedbylongR&Dcycles,highupfrontinvestments,anddelayedvaluerealization.TheCompanyiscurrentlyinarapiddevelopmentphasewhereR&Dpipelinesareenteringacriticalclinicalramp-up.R&Dinvestmentisessentiallyastrategicinvestmentinfutureproducts,pipelineassets,andlong-termcompetitiveness.QualityandefficiencyimprovementdoesnotmeancompressingR&Dinvestment;thecoreistoguidethegrowthofR&Dinvestment to match the pipeline strategic layout and commercializationconversionrhythm.UnderthepremiseofmaintainingcontinuousR&Dgrowth,theconversionefficiencyofeveryunitofR&Dinvestmentwillbeenhanced,achievingboth“investmentgrowthandefficiencyimprovement”.Insummary,theCompanywillcontinuetoinvestinR&Din2027,withaplannedyear-on-yeargrowthofnolessthan10%. ImprovementMeasuresfor“InvestmentGrowthandEfficiencyImprovement”inR&DExpenses: Normalizedpipelinereview,focusingoncoreprojectinvestment:Regularlyreviewpipelineprojects,prioritizingresourceallocationforimportantprojectswith high priority; timely adjust early-stage projects with progress belowexpectationsorweakcompetitiveadvantages,concentratingfundsonprojectswithhighconversionpotential. Refinedprojectbudgetcontrol,trackingactualprogress:Preparebudgetsseparately for each project, strengthen process management during actualexecution,anduseprojectprogressasthebasisforsubsequentbudgetadjustments.SimultaneouslytracktheactualsituationofR&Dinvestment,timelyorganizeinternalreviewsandadjustments,andregularlyreporttheeffectivenessofR&Dinvestmenttomanagement. Optimize external procurement management related to R&D expenses:ConductframeworkpricecomparisonsforcommonCROandotheroutsourcedservices,strivingtosaveunitservicecostsunderthepremiseofincreasinginvestmentscale. (2)NumberofNewClinicalTrialsInitiated TheCompanyisaninnovativebiopharmaceuticalenterprisedrivenbyoutstandingin-houseR&Dcapabilitiesasitscoredrivingforce,withaportfoliocoveringmultipleinnovativetargetsandindicationswithsignificantmarketprospects,includingsmallmolecule drugs, monoclonal antibodies, bispecific antibodies and ADCs for thetreatment of hemato-oncology, various autoimmune diseases and solid tumors.InnovativedrugR&Discharacterizedbylongcycles,highcapitalinvestmentandprominenttechnicalbarriers;thescaleofR&DinvestmentandtheclinicaltriallayoutcanobjectivelyreflectthepaceofpipelineadvancementandarecoreobservationalindicatorsforassessingtheCompany’slong-termgrowthpotential.In2027,theCompanywillcontinuetoadvancetheR&Dandclinicaldevelopmentofvariousinnovativedrugs,andplanstoinitiatenofewerthaneightnewclinicaltrials(includingPhaseI–IIIclinicaltrials,measuredbyfirstpatientenrollment).(II)AnalysisofReturnIndicators 1.SelectionofReturnIndicators
(1)InvestorRelationsManagement TheCompanyhasestablisheda“three-in-one”communicationchannel:regularresponsesviatheSSEe-InteractionPlatform,dedicatedstaffingoftheinvestorhotline,anda24-hourIRemailresponsemechanism.TheCompanyachieveda100%responseratetoinvestorquestionsontheSSEe-InteractionPlatform,effectivelysafeguardingtherighttoknowandparticipateofsmallandmedium-sizedinvestors.TheCompanyproactivelycontactsinvestorsuponthepublicationofperiodicreportsandmajorannouncements.In2026,theCompanyheldthe2025AnnualResultsBriefing,the2026FirstQuarterResultsBriefing,the2026InterimResultsBriefingandthe2026ThirdQuarterResultsBriefing,withallcoremanagementattendingandcommunicatingonline with small and medium-sized investors, establishing a regular meetingmechanism.Inaddition,on14May2026,JisongCui,ChairpersonoftheBoardandChiefExecutiveOfficeroftheCompany,participatedbyvideointhe“DialoguewithGrowth”2025Annualand2026FirstQuarterCollectiveResultsBriefingorganizedbytheSSE,engaginginin-depthexchangeswithindustryleadersonperformancedelivery,profitabilityinflectionpoints,pipelineR&D,overseasexpansion,AIempowermentandotheraspects.TheexchangesshowcasedthecriticaltransitionofChina’sinnovativedrugindustryfromR&Dinvestmenttovaluerealization,shedlightonthelogicofindustrygrowthandtheglobalcompetitivelandscape,anddeliveredauthenticandcutting-edgeindustryinsightstoinvestors.In2027,theCompanywillcontinuetooptimizecommunicationchannelswithandqualityofcommunicationforsmallandmedium-sizedinvestors,regularlycarryoutinvestorengagementactivities,andholdnofewerthanfourresultsbriefings. (2)ESGManagement TheCompanyhasestablishedatop-downESGmanagementstructurewithclearresponsibilitiesandauthorities,comprisingtheBoardastheleadingbody,theESGworkinggroupasthecoremanagementlayer,andthefunctionaldepartmentsastheprimaryimplementation units.TheCompany haspublished ESG reports in bothChineseandEnglishforsevenconsecutiveyears.WithoutstandingESGperformance,theCompanywasselectedforthefirsttimeinS&PGlobal’s2026SustainabilityYearbook(ChinaEdition).In2027,theCompanywillcontinuetoimprovethesystemforcollecting,compilinganddisclosingESGdataandinformation,andcompletethedisclosureofthe2026ESGReportwithhighquality,whilefurtheroptimizingtheCompany’sgreenhousegasaccountingsystemandexpandingthescopeofcarbonemissionmeasurementforScope3categories. (III)AnalysisofComplianceIndicators 1.SelectionofComplianceIndicators
(1)CorporateGovernancePolicyDevelopment TheCompany,instrictcompliancewiththerequirementsoftheSecuritiesLawofthePeople’sRepublicofChina,theRulesGoverningtheListingofStocksontheSTARMarketoftheShanghaiStockExchange,andtheRulesGoverningtheListingofSecuritiesonTheStockExchangeofHongKongLimited,dynamicallytrackspolicychangesandimprovesvarioussystemsaccordingly,therebyensuringtheeffectivenessofinstitutionalguidance.In2026,inlightofnewregulatoryrequirementsandtakingintoaccountitsactualcircumstances,theCompanyrevisedtheArticlesofAssociationandotherfiveinternalgovernancepolicies,namelythe“TermsofReferencefortheAuditCommittee”,the“TermsofReferencefortheCompensationCommittee”,the“TermsofReferencefortheNominationCommittee”,the“RulesofProcedureoftheBoard of Directors”and the “Rules of Procedure of the General Meeting”,andformulated one new internal governance policy, namely the “RemunerationManagement System for Directors and Senior Management of InnoCare PharmaLimited”.In2027,theCompanywillcontinuetotrackchangesinlaws,regulationsandregulatoryrules,andupdatethesystemsrelatingtocorporategovernanceinatimelymanner. (2)InformationDisclosure Intermsofinformationdisclosure,theCompanyhasestablishedstandardizedsystems such as the “Management Policies for Information Disclosure” and the“WorkingRulesforDomesticRepresentativesforInformationDisclosure”,andstrictlyfollowsitsinternalprocedures.In2026,nomajorerrorswereidentified,andtheCompanymadehigh-qualityinformationdisclosuretoinvestors.Atthesametime,basedonthecharacteristicsofthebiopharmaceuticalindustryandinvestorconcerns,theCompanyproactivelydiscloses,onavoluntarybasis,theclinicaltrialprogressandkeyR&Ddevelopmentsofmajorpipelineproductssuchasorelabrutinib,mesutoclax,fadeucravacitinib(ICP-488)andzurletrectinib(ICP-723),therebyfurtherenhancingR&Dtransparencyandhelpinginvestorspromptlygraspthedevelopmenttrendsandappreciatethelong-termvalueoftheGroup’sinnovativepipeline.TheCompanyhasreceivedan“A”ratingintheShanghaiStockExchange’sinformationdisclosureworkevaluationfortwoconsecutiveyears.In2027,theCompanywillstrengthenthequalityofinformationdisclosure,tightenthereviewofannouncementpreparation,andensurezeromajordisclosureerrorsandzerocorrections.TheCompanywillalso,withinthecomplianceframework,optimizetheinterpretationofoperatinginformation,enhancetheclarityofindicatorsandstrategicnarratives,reduceinformationasymmetry,andstabilizemarketexpectations. (3)PerformanceofDutiesbytheAuditCommitteeoftheBoard TheCompanycurrentlyfullyperformsthereviewandoversightresponsibilitiesoftheBoard’sAuditCommitteeovertheCompany’sfinancialreports,internalandexternalaudit,internalcontrolandothermatters.In2026,theCompanyheldatotaloffourmeetingsoftheBoard’sAuditCommittee,atwhichtheAuditCommitteeprovidedfullguidanceandreviewonmatterssuchastheCompany’sfinancialreports,internalandexternalaudit,andinternalcontrol.Duringtheauditoftheannualfinancialreport,theAuditCommitteealsoconductedfull-processguidance,oversightandinspectionofthe audit of the financial report through pre-audit, mid-audit and post-auditcommunicationmeetings, ensuring thatthe financialreport fairly, accuratelyandcompletelyreflectedtheCompany’sactualoperatingconditions.In2027,theCompanywillstrivetofurtherimprovethecorporategovernancestructure,effectivelyenhancethe Company’s governance standards, and establish more effective operational,managementandcontrolsystems.TheCompanywillholdnofewerthanfourAuditCommitteemeetingsthroughouttheyear,atwhichtheAuditCommitteewillperformitsreviewandoversightresponsibilitiesinrespectofmatterssuchascontrolworkduringtheannualfinancialreportauditperiod.AuditCommitteemembersshallreceivetrainingatleasttwiceayear. III.Summary of Targets under the “Quality Improvement, EfficiencyEnhancementandHighReturn”ActionPlan ThesummaryofthetargetsundertheCompany’s2027“QualityImprovement,EfficiencyEnhancementandHighReturn”ActionPlanisasfollows: 1.OperatingIndicatorsandActionPlan
TheCompanyhasestablishedamulti-channel,multi-tieredmechanismforroutineinvestor communication and engagement. Investors may communicate with theCompanyandprovidefeedbackthroughthefollowingchannels: InvestorHotline:010-66609913 InvestorEmail:IR@innocarepharma.com InteractivePlatform:SSEe-InteractionPlatformoftheShanghaiStockExchangeTheCompanywill,throughvariousmeanssuchasroutinetelephonecalls,emailcommunications,responsesviaSSEe-Interaction,andregularresultsbriefingsandcollectivereceptiondays,extensivelysolicitinvestors’opinionsandsuggestionsontheCompany’s business development and the “Quality Improvement, EfficiencyEnhancementandHighReturn”2.0ActionPlan,soastocontinuouslyenhancethequalityofthelistedcompanyandinvestorsatisfaction. V. RiskWarningsandOtherNotes TheaboveactionplanwasformulatedbytheCompanybasedonitscurrentoperations and the external environment. Its subsequent implementation may beaffectedbychangesindomesticandoverseasmarketconditions,industrypoliciesandotherfactors,andissubjecttocertainuncertainties.ItdoesnotconstituteacommitmentregardingtheCompany’sfutureoperatingresults.Investorsareadvisedtoexerciserationaljudgmentandpayattentiontoinvestmentrisks. TheBoardofDirectorsofInnoCarePharmaLimited 21November2026 中财网
![]() |